136 related articles for article (PubMed ID: 35975402)
1. The long-term persistence of tumor necrosis factor inhibitors in patients with moderate to severe immune-mediated rheumatic diseases: A nation-wide, population-based real-world study.
Huang JY; Leong PY; Ker A; Chen HH; Wei JC
Int J Rheum Dis; 2022 Nov; 25(11):1295-1305. PubMed ID: 35975402
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the frequency and intensity of COVID-19 in patients with ankylosing spondylitis under anti-TNF therapy.
Türk SM; Öztürk Z; Karataş D; Erkorkmaz Ü; Gönüllü E
Turk J Med Sci; 2022 Apr; 52(2):522-523. PubMed ID: 36161620
[TBL] [Abstract][Full Text] [Related]
3. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
Favalli EG; Sinigaglia L; Becciolini A; Grosso V; Gorla R; Bazzani C; Atzeni F; Sarzi Puttini PC; Fusaro E; Pellerito R; Caporali R
Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
[TBL] [Abstract][Full Text] [Related]
4. Treatment persistence of subcutaneous TNF inhibitors among Australian patients with immune-mediated rheumatic disease (IMRD).
Acar M; Juneja P; Handel M
Open Access Rheumatol; 2018; 10():151-160. PubMed ID: 30568519
[TBL] [Abstract][Full Text] [Related]
5. Treatment patterns among patients with rheumatic disease (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated arthritis (UnA)) treated with subcutaneous TNF inhibitors.
Tymms K; Littlejohn G; Griffiths H; de Jager J; Bird P; Joshua F; Nash P; Handel M; McManus H; Butcher BE; Youssef P
Clin Rheumatol; 2018 Jun; 37(6):1617-1623. PubMed ID: 29667098
[TBL] [Abstract][Full Text] [Related]
6. TNF-alpha inhibitors for ankylosing spondylitis.
Maxwell LJ; Zochling J; Boonen A; Singh JA; Veras MM; Tanjong Ghogomu E; Benkhalti Jandu M; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2015 Apr; (4):CD005468. PubMed ID: 25887212
[TBL] [Abstract][Full Text] [Related]
7. Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence.
Dalén J; Svedbom A; Black CM; Lyu R; Ding Q; Sajjan S; Sazonov V; Kachroo S
Rheumatol Int; 2016 Jul; 36(7):987-95. PubMed ID: 26780533
[TBL] [Abstract][Full Text] [Related]
8. Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.
Favalli EG; Pregnolato F; Biggioggero M; Becciolini A; Penatti AE; Marchesoni A; Meroni PL
Arthritis Care Res (Hoboken); 2016 Apr; 68(4):432-9. PubMed ID: 26556048
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
Silvagni E; Bortoluzzi A; Carrara G; Zanetti A; Govoni M; Scirè CA
BMJ Open; 2018 Sep; 8(9):e021447. PubMed ID: 30206082
[TBL] [Abstract][Full Text] [Related]
10. Comparative persistence of the TNF antagonists in rheumatoid arthritis--a population-based cohort study.
Fisher A; Bassett K; Wright JM; Brookhart MA; Freeman H; Dormuth CR
PLoS One; 2014; 9(8):e105193. PubMed ID: 25141123
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and drug survival of TNF-inhibitors in the treatment of psoriatic arthritis: A prospective cohort study.
Aaltonen K; Heinonen A; Joensuu J; Parmanne P; Karjalainen A; Varjolahti-Lehtinen T; Uutela T; Puurtinen-Vilkki M; Arstila L; Blom M; Sokka T; Nordström D
Semin Arthritis Rheum; 2017 Jun; 46(6):732-739. PubMed ID: 28010883
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis.
Canhão H; Rodrigues AM; Mourão AF; Martins F; Santos MJ; Canas-Silva J; Polido-Pereira J; Pereira Silva JA; Costa JA; Araújo D; Silva C; Santos H; Duarte C; da Silva JA; Pimentel-Santos FM; Branco JC; Karlson EW; Fonseca JE; Solomon DH
Rheumatology (Oxford); 2012 Nov; 51(11):2020-6. PubMed ID: 22843791
[TBL] [Abstract][Full Text] [Related]
13. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
[TBL] [Abstract][Full Text] [Related]
14. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
Li N; Betts KA; Messali AJ; Skup M; Garg V
Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
[TBL] [Abstract][Full Text] [Related]
15. The Effect of Tumor Necrosis Factor-Alpha Inhibitors on Uveitis in Patients with Ankylosing Spondylitis.
Lee S; Park YJ; Lee JY
J Korean Med Sci; 2019 Nov; 34(42):e278. PubMed ID: 31674159
[TBL] [Abstract][Full Text] [Related]
16. One-Year Tuberculosis Risk in Rheumatoid Arthritis Patients Starting Their First Tumor Necrosis Factor Inhibitor Therapy from 2008 to 2012 in Taiwan: A Nationwide Population-Based Cohort Study.
Lim CH; Lin CH; Chen DY; Chen YM; Chao WC; Liao TL; Chen HH
PLoS One; 2016; 11(11):e0166339. PubMed ID: 27832150
[TBL] [Abstract][Full Text] [Related]
17. Health-Care and Societal Costs Associated with Non-Persistence with Subcutaneous TNF-α Inhibitors in the Treatment of Inflammatory Arthritis (IA): A Retrospective Observational Study.
Dalén J; Chitkara A; Svedbom A; Olofsson T; Puenpatom A; Black CM; Qureshi ZP
Adv Ther; 2022 Jun; 39(6):2468-2486. PubMed ID: 34751912
[TBL] [Abstract][Full Text] [Related]
18. Persistence of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: An analysis of the South Korean National Health Insurance Database.
Lee MY; Shin JY; Park SY; Kim D; Cha HS; Lee EK
Semin Arthritis Rheum; 2018 Feb; 47(4):485-491. PubMed ID: 28939234
[TBL] [Abstract][Full Text] [Related]
19. Patient self-reported experience and satisfaction with golimumab and etanercept treatments for rheumatic diseases: A cohort study.
Xia W; Zhou L; Gao W; Zhang Y; Si F; Bai F; Zhang Z; Wang W; Chen G; Gao C; Li X; Yue T
Medicine (Baltimore); 2024 Feb; 103(8):e36982. PubMed ID: 38394542
[TBL] [Abstract][Full Text] [Related]
20. Effect of Comedication With Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Retention of Tumor Necrosis Factor Inhibitors in Patients With Spondyloarthritis: A Prospective Cohort Study.
Sepriano A; Ramiro S; van der Heijde D; Ávila-Ribeiro P; Fonseca R; Borges J; Teixeira L; Carvalho PD; Cerqueira M; Neves J; Meirinhos T; Barcelos A; Sequeira G; Salvador MJ; Canas da Silva J; Santos H; Bernardes M; Vieira-Sousa E; Canhão H; Branco JC; Pimentel-Santos F; Landewé R
Arthritis Rheumatol; 2016 Nov; 68(11):2671-2679. PubMed ID: 27273894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
